Elcelyx's delayed-release metformin meets in Phase IIb

Elcelyx Therapeutics Inc. (San Diego, Calif.) said once-daily oral NewMet met the primary endpoint of reducing fasting plasma glucose (FPG) from baseline to week four vs. placebo in a Phase IIb trial to treat Type II diabetes. The double-blind, dose-finding, U.S. trial enrolled 240 Type II diabetics to receive placebo; once-daily 600, 800 or 1,000 mg NewMet, a delayed-release formulation of metformin; or once-daily doses of a generic extended-release formulation of metformin. Elcelyx expects to report 12-week data from the trial in October. ...